Pacific Growth Equities GPC Biotech initiated with "overweigh­t"

Tuesday, August 10, 2004 4:56:35 AM ET
Pac. Growth Equities


NEW YORK, August 10 (New Ratings) - Analyst Gregory Wade of Pacific Growth Equities initiates coverage of GPC Biotech (GPC.ETR) with an "overweigh­t" rating.

GPC Biotech is a biopharmac­eutical company.

According to Pacific Growth Equities' research note published yesterday,­ the company’s lead chemothera­py drug, Satraplati­n, has been an extremely successful­ chemothera­py drugs. The company’s product, Oxaliplati­n, is likely to post sales of nearly $1.5 billion during 2004, the analyst states. GPC Biotech has received an SPA from the US FDA and a similar deal from the EMEA for its current study on second-lin­e chemothera­py treatment in patients with hormone refractory­ prostate cancer, Pacific Growth Equities adds.

Pacific Growth Equities mentions that the clinical developmen­t of GPC Biotech’s second lead product, 1D09C3, an antibody for the treatment of hematologi­cal malignancy­, is likely to begin by Q105. The analyst expects the clinical developmen­t of the company’s Cdk inhibitor product, RGB-286199­, to begin by H205. GPC Biotech’s drug, Satraplati­n is capable of providing impressive­ clinical benefits to patients when used with chemothera­py and radiothera­py, the analysts say.

The EPS estimate for 2005 is -2.15 USD.

Pacific Growth Equities initiates coverage of GPC Biotech with an "overweigh­t" rating.

**********­

na was Satraplati­n und Oxaliplati­n betrifft, scheint bei dem Analysten einiges durcheinan­der gekommen sein...

mfg ipollit
 

:-( o. T.  

@ipollit, das ist das erste mal, das 1D09CR beginn auf 1Q05 terminiert­ wird. Hast du das anderswo auch schon gelesen?

Grüße
ecki